Sai Life Sciences
924.75
+13.60(+1.49%)
Market Cap₹19,279.73 Cr
PE Ratio77.88
IndustryHealthcare
Company Performance:
1D+1.49%
1M+14.68%
6M+31.03%
1Y+20.94%
5Y+20.94%
View Company Insightsright
More news about Sai Life Sciences
19Jun 25
TPG Asia to Offload 6% Stake in Sai Life Sciences for ₹887.5 Crore
TPG Asia plans to divest a 6% stake in Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization. The block deal involves 12.5 million shares priced at ₹710.00 each, a 2.5% discount to the market price. The total deal value is approximately ₹887.50 crore ($102 million). A 60-day lock-in period will be imposed on TPG Asia post-transaction.
14May 25
Sai Life Sciences Sets Ambitious Growth Targets, Eyes Margin Expansion
Sai Life Sciences, a leading CRDMO, has announced plans for significant expansion. The company aims for a 15-20% CAGR in revenues over the next 3-5 years and targets to increase profit margins from 24% to 30%. In Q4FY25, the company reported revenue of ₹579.00 crore with a 27.20% profit margin. Sai Life Sciences sees growth opportunities in the global trend of diversifying pharmaceutical supply chains away from China, particularly due to pricing uncertainties in the US market.
04Apr 25
Sai Life Sciences Expands Research Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The facility features state-of-the-art technology for complex peptide synthesis and conjugation, including automation and robotics. This expansion aims to meet the growing demand for peptide-based therapeutics and reinforces the company's position in advancing next-generation drugs. The center will offer specialized services in peptide synthesis, discovery, and advanced modalities, integrated with Sai Life Sciences' existing end-to-end discovery services.
03Apr 25
Sai Life Sciences Expands Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The state-of-the-art facility integrates automation, advanced liquid handling, robotics, and high-throughput systems to enhance peptide research and development. It offers specialized services in peptide synthesis, discovery, and advanced modalities, supporting innovator pharma and biotech companies. The center is integrated with Sai Life Sciences' existing end-to-end discovery services, aiming to accelerate timelines for peptide-based drug development.
Sai Life Sciences
924.75
+13.60
(+1.49%)
1 Year Returns:+20.94%
Industry Peers
Sun Pharmaceutical
1,640.20
(+0.43%)
Divis Laboratories
6,028.00
(+0.38%)
Cipla
1,592.80
(+3.02%)
Torrent Pharmaceuticals
3,647.40
(-0.45%)
Mankind Pharma
2,600.10
(+3.73%)
Dr Reddys Laboratories
1,276.60
(+2.51%)
Zydus Life Science
985.80
(+0.25%)
Lupin
1,962.50
(+1.14%)
Abbott
32,635.00
(+0.12%)
Alkem Laboratories
5,422.00
(+0.54%)